Neurocrine Biosciences NBIX
NASDAQ NBIX
$141.31 -0.69 (-0.49%)
At close: Oct 21, 2026 · 4:00 PM EDT

Neurocrine Biosciences (NBIX) Other financing activities (2026)

Updated

Neurocrine Biosciences' Other financing activities was $2.7 million in Q2 2026, down 95.2% from the prior quarter.

Analysis

Neurocrine Biosciences (NBIX) Other financing activities (2026) Analysis & Trends

On a trailing twelve-month basis, Neurocrine Biosciences' Other financing activities was $58.4 million through Jun 30, 2026.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Neurocrine Biosciences 14.29 Bn 9.99 Bn 935.80 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -9.40 Mn
Mar 31, 2026 -55.70 Mn
API Access

Neurocrine Biosciences Other financing activities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-financing-activities&ticker=NBIX&period=max&api_key=YOUR_API_KEY